Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
BURLINGTON, Mass., April 30, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2018 financial results after the close of the U.S. financial markets on Tuesday, May 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2880817. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was also recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
